ReviewCurrent treatment options in allergy2016
Mast Cell Clonal Disorders: Classification, Diagnosis and Management.
Review in Current treatment options in allergy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 24 citations in OpenAlex.
- Impact of Molecular Evaluations in the Biology, Diagnosis, and Prognostication of Patients With Mastocytosis.The journal of allergy and clinical immunology. In practice · 2026Review
- Avapritinib for the treatment of KIT mutation-negative systemic mastocytosis.Proceedings (Baylor University. Medical Center) · 2023Article
- Common immunopathogenesis of central nervous system diseases: the protein-homeostasis-system hypothesis.Cell & bioscience · 2022Review
- Rare gastrointestinal presentation of systemic mastocytosis, a case report.Annals of medicine and surgery (2012) · 2022Article
- Novel Strategies to Target Mast Cells in Disease.Journal of innate immunity · 2021Review
- Genotypic and phenotypic characteristics of Chinese neonates with cutaneous mastocytosis: a case report and literature review.The Journal of international medical research · 2020Review
- Exercise-induced anaphylaxis with an Ayurvedic drug as cofactor: A case report.World journal of clinical cases · 2019Article
- Clinical Implications of Tumor-Infiltrating Immune Cells in Breast Cancer.Journal of Cancer · 2019Article
- Novel approaches to treating advanced systemic mastocytosis.Clinical pharmacology : advances and applications · 2019Review
- Mastocytosis in Children.Current allergy and asthma reports · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mast cell clonal disorders are characterized by the clonal proliferation of pathological mast cells as a result of somatic mutations in the KIT gene, most commonly the D816V mutation. Accumulation and degranulation of these cells causes a wide variety of symptoms. Mast cell clonal disorders can be divided into mastocytosis and monoclonal mast cell activation syndrome, depending of the level of clonality. The severity of mastocytosis varies from an indolent variant with a good prognosis, to an aggressive condition with short life expectancy. Diagnosis is based on demonstration of clonality and accumulation in the skin and in extracutaneous tissues. Treatment is highly individualized, and is based on the severity of the condition. Treatment of patients with indolent systemic mastocytosis is aimed at reducing symptoms, using histamine H1 and H2 receptor antagonists as a starting point. In addition, associated conditions such as osteoporosis must be treated. Treatment of advanced systemic mastocytosis is aimed at reducing mast cell load through cytoreductive therapy. The choice of such therapy depends on the KIT mutational status. Though currently there is no curative treatment available, promising new therapies such as midostaurin are emerging that have demonstrated success in reducing symptoms and improving quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.